Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04491409 · ClinicalTrials.gov registry record

Perioperative Care in the Cancer Patient -1, ARCA-1 Study

A clinical trial of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
229
Enrollment target
1
Study location

NCT04491409: Completed study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

NCT04491409 is a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 229 participants, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04491409, a study of Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
229 participants
Enrollment target
1
Study location

Study Summary

This study investigates the association of blood transfusions given around the time of surgery (perioperative) with complications after surgery (postoperative), cancer progression, and mortality after major oncologic non-cardiac surgery. The administration of blood products is an important clinical therapy to treat life-threatening blood (hematological) disorders (i.e. anemia, coagulation disorders or thrombocytopenia) in patients with cancer undergoing major non-cardiac surgery. On the other hand, the unnecessary exposure of those patients to blood products can be associated with the occurrence of unwanted severe complications and potentially increase the risk of death. An accurate understanding of the short and long-term outcomes, the patterns of blood transfusions, and the triggers of blood product administration may help researchers design and test the safety of perioperative blood transfusions in patients with cancer.

Interventions

  • OTHER Medical Chart Review
  • OTHER Best Practice

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 229 participants
Start Date 2020-08-03
Est. Completion 2023-11-17
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT04491409 record still lists

NCT04491409 is an observational study that tracks outcomes without assigning an intervention. The registered 229 participants enrollment target is mid-sized for trials with a published cap, below the 1,140-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (80% lower).

The record links to 2 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Medical Chart Review is the first listed.

NCT04491409 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04491409 about?

NCT04491409 is a clinical study titled "Perioperative Care in the Cancer Patient -1, ARCA-1 Study". This study investigates the association of blood transfusions given around the time of surgery (perioperative) with complications after surgery (postoperative), cancer progression, and mortality after major oncologic non-cardiac surgery. The administration of blood products is an important clinical ...

What is the current status of trial NCT04491409?

This trial is currently completed. The enrollment target is 229 participants. The study started on 2020-08-03. Estimated completion is 2023-11-17.

What conditions does trial NCT04491409 study?

This clinical trial studies the following conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT04491409?

The interventions under investigation include: Medical Chart Review (OTHER), Best Practice (OTHER).

Who is sponsoring clinical trial NCT04491409?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04491409 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Solid Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04491409's enrollment target sits among peer trials

229 58th of 176 higher than 119 of 176 other Malignant Solid Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04491409, the US trial registry maintained by the National Library of Medicine. NCT04491409 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.